SCHEMBL5234199

SCHEMBL5234199

O=C1[C@H](Cc2ccc(Cl)c(Cl)c2)N(Cc2ccncc2)C(=O)CCN1Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WDR5 P61964 1/20 0.37
▸ TACR1 P25103 5/20 0.36
▸ USP2 O75604 4/20 0.36
▸ CYP3A4 P08684 4/20 0.36
▸ HIF1A Q16665 3/20 0.36
▸ TSHR P16473 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ ROCK2 O75116 1/20 0.35
▸ ROCK1 Q13464 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ CYP2C9 P11712 2/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ P2RX7 Q99572 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ ITGB2 P05107 1/20 0.34
▸ ICAM1 P05362 1/20 0.34
▸ ITGAL P20701 1/20 0.34
▸ HDAC6 Q9UBN7 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5234192 1.00 WDR5 (0.37) WDR5TACR1USP2CYP3A4HIF1A
SCHEMBL5235531 0.91 MAPT (0.42) WDR5HIF1AMAPTALDH1A1P2RX7
SCHEMBL5235528 0.91 MAPT (0.42) WDR5HIF1AMAPTALDH1A1P2RX7
SCHEMBL5237223 0.87 HDAC1 (0.39) WDR5TACR1P2RX7HDAC6HDAC1
SCHEMBL5234746 0.85 TACR1 (0.33) WDR5TACR1ALDH1A1
SCHEMBL5229738 0.84 CNR2 (0.38) TACR1ALDH1A1
SCHEMBL5235420 0.79 TACR1 (0.37) TACR1MAPTSMN1; SMN2ALDH1A1
SCHEMBL5235425 0.79 TACR1 (0.37) TACR1MAPTSMN1; SMN2ALDH1A1
SCHEMBL5232486 0.78 WDR5 (0.35) WDR5TACR1ALDH1A1
SCHEMBL5229630 0.75 TACR1 (0.48) WDR5TACR1HDAC6HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452001-B2 1,4-DIAZEPINE-2-ONE DERIVATIVES AS NEUROKININ ANTAGONIST HOFFMANN-LA ROCHE INC. 2002-09-17 — — US claimed
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 — — US claimed
EP-1296961-B1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2007-02-14 — — EP disclosed
EP-1296961-A1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-04-02 — — EP disclosed
US-6452001-B2 1,4-DIAZEPINE-2-ONE DERIVATIVES AS NEUROKININ ANTAGONIST HOFFMANN-LA ROCHE INC. 2002-09-17 — — US disclosed
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 — — US disclosed
WO-2001090083-A1 1,4-DIAZEPAN-2,5-DIONE DERIVATIVES AND THEIR USE AS NK-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010174-A1 Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation BDKRB2, NPSR1, BDKRB1 WDR5 3581/4885TACR1 8/4885USP2 3720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback